MedTrace Logo

Effect of HSV-2 Suppressive Therapy on Sexual Behavior

NCT00495716 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2023-03-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine what effect suppressive therapy has on sexual behavior and quality of life among persons with genital herpes (HSV) who have multiple sex partners.

Study terminated; investigator relocated and study funding ended. Results were never analyzed because data were not collected.

Conditions

  • Genital Herpes

Interventions

DRUG

acyclovir

800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence

DRUG

acyclovir

400 mg acyclovir orally twice daily for 1 year

Sponsors & Collaborators

Principal Investigators

  • Anna Wald, MD, MPH · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00495716 on ClinicalTrials.gov